- Home
- RGEN
RGEN
Repligen Corporation
as 07-26-2024 4:00pm EST
Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America.
Upcoming Earnings Alert:
Get ready for potential market movements as Repligen Corporation RGEN prepares to release earnings report on 30 Jul 2024.
| Founded: | 1981 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 7.0B | IPO Year: | N/A |
| Target Price: | $193.00 | AVG Volume (30 days): | 732.6K |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.27 | EPS Growth: | -90.85 |
| 52 Week Low/High: | $110.45 - $211.13 | Next Earning Date: | 07-30-2024 |
| Revenue: | $607,450,000 | Revenue Growth: | -21.90% |
| Revenue Growth (this year): | 1.63% | Revenue Growth (next year): | 15.56% |
Stock Insider Trading Activity of Repligen Corporation (RGEN)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| BARTHELEMY NICOLAS | RGEN | Director | Jun 14 '24 | Buy | $125.45 | 1,200 | $150,540.00 | 4,668 | SEC Form 4 |
| Madaus Martin D | RGEN | Director | Jun 14 '24 | Buy | $125.46 | 700 | $87,822.00 | 4,613 | SEC Form 4 |
| Madaus Martin D | RGEN | Director | Jun 14 '24 | Buy | $124.54 | 915 | $113,954.10 | 3,913 | SEC Form 4 |
| Hunt Anthony | RGEN | Chief Executive Officer | Jun 14 '24 | Buy | $124.08 | 2,000 | $248,160.00 | 165,177 | SEC Form 4 |
| Hunt Anthony | RGEN | Chief Executive Officer | May 21 '24 | Sell | $166.36 | 4,274 | $711,022.64 | 178,975 | SEC Form 4 |
| Hunt Anthony | RGEN | Chief Executive Officer | May 21 '24 | Sell | $167.05 | 4,008 | $669,536.40 | 174,967 | SEC Form 4 |
| Hunt Anthony | RGEN | Chief Executive Officer | May 21 '24 | Sell | $168.33 | 3,933 | $662,041.89 | 171,034 | SEC Form 4 |
| Hunt Anthony | RGEN | Chief Executive Officer | May 21 '24 | Sell | $169.27 | 2,963 | $501,547.01 | 168,071 | SEC Form 4 |
| Hunt Anthony | RGEN | Chief Executive Officer | May 21 '24 | Sell | $170.04 | 3,925 | $667,407.00 | 164,146 | SEC Form 4 |
| Hunt Anthony | RGEN | Chief Executive Officer | May 21 '24 | Sell | $171.03 | 969 | $165,728.07 | 163,177 | SEC Form 4 |
| KURIYEL RALF | RGEN | Senior VP, R&D | Mar 11 '24 | Sell | $193.73 | 3,517 | $681,348.41 | 24,260 | SEC Form 4 |
| Hunt Anthony | RGEN | Chief Executive Officer | Mar 8 '24 | Sell | $202.55 | 156 | $31,597.80 | 185,249 | SEC Form 4 |
| Hunt Anthony | RGEN | Chief Executive Officer | Mar 8 '24 | Sell | $201.75 | 806 | $162,610.50 | 185,405 | SEC Form 4 |
| Hunt Anthony | RGEN | Chief Executive Officer | Mar 8 '24 | Sell | $200.56 | 1,305 | $261,730.80 | 186,211 | SEC Form 4 |
| Hunt Anthony | RGEN | Chief Executive Officer | Mar 8 '24 | Sell | $199.53 | 1,822 | $363,543.66 | 187,516 | SEC Form 4 |
| Hunt Anthony | RGEN | Chief Executive Officer | Mar 8 '24 | Sell | $198.55 | 1,347 | $267,446.85 | 189,338 | SEC Form 4 |
| Hunt Anthony | RGEN | Chief Executive Officer | Mar 8 '24 | Sell | $197.39 | 1,666 | $328,851.74 | 190,685 | SEC Form 4 |
| Hunt Anthony | RGEN | Chief Executive Officer | Mar 8 '24 | Sell | $196.32 | 6,228 | $1,222,680.96 | 192,351 | SEC Form 4 |
| Hunt Anthony | RGEN | Chief Executive Officer | Mar 8 '24 | Sell | $195.49 | 3,377 | $660,169.73 | 198,579 | SEC Form 4 |
| DAWES KAREN A | RGEN | Director | Feb 27 '24 | Sell | $193.35 | 1,000 | $193,350.00 | 87,367 | SEC Form 4 |
| Bylund James | RGEN | Chief Operating Officer | Feb 23 '24 | Sell | $198.08 | 4,373 | $866,203.84 | 14,135 | SEC Form 4 |
| Gebski Christine | RGEN | See Remarks | Nov 10 '23 | Sell | $147.13 | 3,788 | $557,328.44 | 28,787 | SEC Form 4 |
Latest Repligen Corporation News
RGEN Breaking Stock News: Dive into RGEN Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
Exact Sciences (EXAS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Argus Research
3 days ago
RGEN: Lowering target price to $116.00
Zacks
3 days ago
Analysts Estimate Repligen (RGEN) to Report a Decline in Earnings: What to Look Out for
Insider Monkey
7 days ago
Repligen Corporation (RGEN): Why Are Hedge Funds Bullish On This Profitable Stock Right Now?
Simply Wall St.
9 days ago
Exploring Three Stocks Estimated to Trade Below Intrinsic Value With Discounts Up to 31%
Argus Research
10 days ago
RGEN: Rating decreased to a SELL
GlobeNewswire
11 days ago
Repligen to Report Second Quarter 2024 Financial Results
MT Newswires
11 days ago
Repligen Reports Attempted Cybersecurity Incident
Compare RGEN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RGEN Repligen Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.